CFA
IRD

Camarda Financial Advisors’s Opus Genetics IRD Stock Holding History

Camarda Financial Advisors’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2
Closed – – 200
2017
Q4 		$0 Hold
2
– – ﹤0.01% 225
2017
Q3 		$0 Buy
+2
New +$216 ﹤0.01% 251

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Camarda Financial Advisors's IRD Position: Q1 2018 in Review

Camarda Financial Advisors sold out of Opus Genetics (IRD) in Q1 2018, closing a stake of 2 shares.

Camarda Financial Advisors first reported a position in IRD in Q3 2017 and held it in 2 quarters. The position peaked at $0 in Q4 2017. 26 funds tracked by Wall St. Rank hold IRD as of Q1 2018.

  • Camarda Financial Advisors reported no remaining Opus Genetics position as of Q1 2018 after selling out during the quarter.
  • Camarda Financial Advisors sold 2 Opus Genetics shares in Q1 2018.
  • Camarda Financial Advisors first reported a position in Opus Genetics in Q3 2017 and held it in 2 quarters.
  • Camarda Financial Advisors's Opus Genetics position peaked at $0 in Q4 2017.
  • 26 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2018.

Based on Camarda Financial Advisors's 13F filing for Q1 2018, filed 30 Apr 2018.